阿德福韦酯治疗活动性乙型肝炎肝硬化的临床研究被引量：1

导出

摘要目的:观察阿德福韦酯治疗活动性乙型肝炎肝硬化的疗效及不良反应。方法:选择70例活动性乙型肝炎肝硬化的患者,随机分成观察组和对照治疗组各35例。两组均予以常规综合护肝治疗,观察组加用阿德福韦酯片剂10mg/d治疗,连续治疗12个月。分别观察治疗前后的肝功能、HBV血清标志物、HBV-DNA水平变化及Child-Pugh评分。结果:观察组患者的肝功能、HBV血清标志物、HBV-DNA水平变化及Child-Pugh评分,均明显优于对照组患者(P<0.05)。结论:阿德福韦酯治疗活动性乙型肝炎肝硬化的疗效优于常规护肝治疗,且不良反应发生率更低。

作者金锦莲吴发明张毅谢晓晶唐鹏

机构地区三峡大学第三临床医学院湖北省葛洲坝集团中心医院消化内科

出处《临床急诊杂志》 CAS 2011年第3期191-193,共3页 Journal of Clinical Emergency

关键词阿德福韦酯乙型肝炎肝硬化

分类号 R512.6 [医药卫生—内科学]

引文网络
相关文献

参考文献5

1中华医学会传染病与奇乍虫病分公肝病学分会.痫毒性肝炎防治方案.中华传染痫杂志,2000,19(1):5662-5662.
2曾民德,茅益民,姚光弼,周霞秋,王豪,徐道振,姚集鲁,侯金林,王宇明,任红,陈亚岗,牛俊奇,王耀宗.阿德福韦酯治疗HBeAg阳性的中国慢性乙型病毒性肝炎患者52周的多中心临床研究[J].中华传染病杂志,2005,23(6):387-394. 被引量：164
3HADZIYANNIS S J. New developments in the treat- ment of chronic hepatitis B[J]. Expert Opin Biol T- her, 2006,6 : 913 - 921.
4WERLE B, CINQUIN K, MARCELLIN P, et al. Evo- lution of hepatitis B viral load and viral genome se- quence during adefovir dipivoxil therapy[J]. J viralHepat,2004,11:74-81.
5MARCELLIN P,CHANG T I,LIM S G,et al. Adefo- virdipioxil for the treatment of hepatitis B e antigen- positive chronic hepatitis B[J]. N Engl J Med, 2003, 348:808-816.

二级参考文献19

1Hadziyannis S,Tassopoulos N,Chang TT,et al.Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B patients in a long-term safety and efficacy study.J Hepatol,2004,40(Suppl 1):17 (Abstract 46).
2Hadziyannis SJ,Papatheodoridis GV.Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection.Expert Rev Anti Infect Ther,2004,2:475-483.
3Marcellin P,Chang TT,Lim SG,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.N Engl J Med,2003,348:808-816.
4Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.N Engl J Med,2003,348:800-807.
5Cullen JM,Li DH,Brown C,et al.Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks.Antimicrob Agents Chemother,2001,45:2740-2745.
6Delmas J,Schorr O,Jamard C,et al.Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro.Antimicrob Agents Chemother,2002,46:425-433.
7Werle-Lapostolle B,Bowden S,Locarnini S,et al.Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.Gastroenterology,2004,126:1750-1758.
8Lok AS,McMahon BJ.Chronic hepatitis B:update of recommendations.Heptology,2004,39:857-861.
9Qi X,Snow A,Thibault V,et al.Long-term incidence of Adefovir Dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy.Hepatol,2004,40(Suppl 1):20 (Abstract 57).
10Westland CE,Yang H,Delaney WE 4th,et al.Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.Hepatology,2003,38:96-103.